ASAM Pocket Guidelines and Patient Guide

ASAM Opioid Use Disorder Patient Guide 2025

ASAM Opioid Addiction Treatment GUIDELINES Apps and Pocket Guides brought to you courtesy of Guideline Central. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1536453

Contents of this Issue

Navigation

Page 6 of 23

7 MEDICATIONS TO TREAT OPIOID ADDICTION Medication Brand Names Buprenorphine Sublocade® (Injection), Brixadi® (injection), generics (films or tablets) Buprenorphine and naloxone Bunavail®, Cassipa®, Suboxone®, Zubsolv®, generics (films or tablets) Methadone generics (liquid or tablets to dissolve in water) Extended release naltrexone Vivitrol® (injection) WITHDRAWAL • Opioid withdrawal refers to the wide range of painful and unpleasant symptoms (such as vomiting, diarrhea, and muscle pain) that occur after stopping or cutting down on the use of opioids. Withdrawal can last more than 10 days but is most often between 3–5 days. • While rare, opioid withdrawal can be life threatening. • Using medications to control withdrawal (also called withdrawal management) is almost always recommended over trying to endure withdrawal without treatment. When patients do try to stop using opioids without treatment it can lead to stronger cravings and continued use. • Withdrawal management on its own is not a treatment for opioid addiction and may increase the risk of relapse, overdose, and overdose death. • Methadone and buprenorphine can treat both opioid withdrawal and opioid addiction and are usually recommended. • Lofexidine and clonidine are safe and effective for management of opioid withdrawal, but methadone and buprenorphine are more effective. • Opioid withdrawal management using ultra-rapid opioid detoxification (UROD) is NOT recommended due to high risk for adverse events including death.

Articles in this issue

view archives of ASAM Pocket Guidelines and Patient Guide - ASAM Opioid Use Disorder Patient Guide 2025